EA202092451A1 - Соединения - Google Patents

Соединения

Info

Publication number
EA202092451A1
EA202092451A1 EA202092451A EA202092451A EA202092451A1 EA 202092451 A1 EA202092451 A1 EA 202092451A1 EA 202092451 A EA202092451 A EA 202092451A EA 202092451 A EA202092451 A EA 202092451A EA 202092451 A1 EA202092451 A1 EA 202092451A1
Authority
EA
Eurasian Patent Office
Prior art keywords
connections
compound
formula
pharmaceutical salt
pharmaceutical
Prior art date
Application number
EA202092451A
Other languages
English (en)
Russian (ru)
Inventor
Пол Энтони Стаппл
Хелен Рейчел Лагиакос
Бенджамин Джозеф Морроу
Ричард Чарльз Фоитзик
Кэтрин Фей Хемли
Мишель Анг Камерино
Илва Элизабет Бергман Бозикис
Скотт Реймонд Уокер
Original Assignee
СиТиЭксТи ПТИ ЛИМИТЕД
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by СиТиЭксТи ПТИ ЛИМИТЕД filed Critical СиТиЭксТи ПТИ ЛИМИТЕД
Publication of EA202092451A1 publication Critical patent/EA202092451A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
EA202092451A 2018-06-20 2019-06-20 Соединения EA202092451A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1810092.5A GB201810092D0 (en) 2018-06-20 2018-06-20 Compounds
PCT/EP2019/066337 WO2019243491A1 (en) 2018-06-20 2019-06-20 Compounds

Publications (1)

Publication Number Publication Date
EA202092451A1 true EA202092451A1 (ru) 2021-03-16

Family

ID=63042663

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092451A EA202092451A1 (ru) 2018-06-20 2019-06-20 Соединения

Country Status (39)

Country Link
US (2) US20200039945A1 (pt)
EP (2) EP4335439A3 (pt)
JP (1) JP2021529738A (pt)
KR (1) KR20210022655A (pt)
CN (1) CN112334466A (pt)
AR (1) AR114972A1 (pt)
AU (1) AU2019289888A1 (pt)
BR (1) BR112020025869A2 (pt)
CA (1) CA3101238A1 (pt)
CL (1) CL2020003219A1 (pt)
CO (1) CO2020014586A2 (pt)
CR (1) CR20210032A (pt)
CU (1) CU20200096A7 (pt)
DK (1) DK3810602T3 (pt)
DO (1) DOP2020000249A (pt)
EA (1) EA202092451A1 (pt)
EC (1) ECSP20075270A (pt)
ES (1) ES2967983T3 (pt)
FI (1) FI3810602T3 (pt)
GB (1) GB201810092D0 (pt)
GE (1) GEP20227403B (pt)
HR (1) HRP20231467T1 (pt)
HU (1) HUE064744T2 (pt)
IL (1) IL279554A (pt)
LT (1) LT3810602T (pt)
MA (1) MA52948B1 (pt)
MD (1) MD3810602T2 (pt)
MX (1) MX2020012723A (pt)
NI (1) NI202000092A (pt)
PE (1) PE20210181A1 (pt)
PH (1) PH12020500673A1 (pt)
PL (1) PL3810602T3 (pt)
PT (1) PT3810602T (pt)
RS (1) RS64932B1 (pt)
SG (1) SG11202010450VA (pt)
SI (1) SI3810602T1 (pt)
TW (1) TWI826471B (pt)
UY (1) UY38270A (pt)
WO (1) WO2019243491A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3471271A1 (en) 2017-10-16 2019-04-17 Acoustical Beauty Improved convolutions of digital signals using a bit requirement optimization of a target digital signal
ES2969616T3 (es) * 2019-06-18 2024-05-21 Pfizer Derivados de benzisoxazol sulfonamida
US20220251075A1 (en) * 2019-06-19 2022-08-11 Pfizer Inc. Cycloalkyl and Heterocycloalkyl Benzisoxazole Sulfonamide Derivatives
US12012373B2 (en) 2019-07-12 2024-06-18 Canopy Growth Corporation Cannabinoid derivatives
CN116113407A (zh) 2020-07-15 2023-05-12 辉瑞公司 用于癌症治疗的kat6抑制剂方法及组合
WO2022243983A1 (en) * 2021-05-21 2022-11-24 Aurigene Discovery Technologies Limited Fused isoxazolyl compounds as kat6a inhibitors
EP4368620A1 (en) * 2021-07-05 2024-05-15 Hangzhou Innogate Pharma Co., Ltd. Compound serving as kat6 inhibitor
KR20240046530A (ko) 2021-08-10 2024-04-09 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 설폰아미드 유도체, 이의 제조 방법 및 이의 의학적 용도
AU2022390319A1 (en) * 2021-11-16 2024-05-30 Insilico Medicine Ip Limited Lysine acetyltransferase 6a (kat6a) inhibitors and uses thereof
WO2023114710A1 (en) * 2021-12-13 2023-06-22 Aurigene Oncology Limited Fused benzoisoxazolyl compounds as kat6a inhibitors
US20230303580A1 (en) * 2022-03-28 2023-09-28 Isosterix, Inc. Inhibitors of the myst family of lysine acetyl transferases
US20230416240A1 (en) * 2022-06-16 2023-12-28 Prelude Therapeutics Incorporated Kat6 targeting compounds
WO2024023703A1 (en) 2022-07-29 2024-02-01 Pfizer Inc. Dosing regimens comprising a kat6 inhibitor for the treatment of cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
SK285141B6 (sk) 1996-02-13 2006-07-07 Astrazeneca Uk Limited Použitie chinazolínového derivátu, chinazolínový derivát, spôsob jeho prípravy a farmaceutická kompozícia, ktorá ho obsahuje
EP0885198B1 (en) 1996-03-05 2001-12-19 AstraZeneca AB 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
JP4367866B2 (ja) 1997-02-12 2009-11-18 ザ リージェンツ オブ ジ ユニバーシティ オブ ミシガン 肺癌用のタンパク質マーカーおよびその使用
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EE05345B1 (et) 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
ES2306306T3 (es) 1999-11-05 2008-11-01 Astrazeneca Ab Nuevos derivados de quinazolina.
CZ303705B6 (cs) 2000-02-15 2013-03-27 Sugen, Inc. Pyrrolem substituovaná 2-indolinonová sloucenina pro pouzití jako inhibitor proteinkináz a farmaceutická kompozice s jejím obsahem
MXPA02011770A (es) 2000-05-31 2003-04-10 Astrazeneca Ab Derivados de indol con actividad de dano vascular.
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
WO2002008213A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
MX2011007424A (es) * 2009-01-12 2011-08-12 Icagen Inc Derivados de sulfonamida.
EP2970156B1 (en) * 2013-03-15 2018-07-25 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
WO2015163339A1 (ja) * 2014-04-23 2015-10-29 田辺三菱製薬株式会社 新規二環性または三環性複素環化合物
GB201510019D0 (en) 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
EP3548480A1 (en) * 2016-11-29 2019-10-09 Epizyme, Inc. Compounds containing a sulfonic group as kat inhibitors
ES2969616T3 (es) * 2019-06-18 2024-05-21 Pfizer Derivados de benzisoxazol sulfonamida

Also Published As

Publication number Publication date
GEP20227403B (en) 2022-08-10
WO2019243491A1 (en) 2019-12-26
SI3810602T1 (sl) 2024-02-29
CN112334466A (zh) 2021-02-05
HRP20231467T1 (hr) 2024-03-01
PT3810602T (pt) 2024-01-03
PL3810602T3 (pl) 2024-03-04
JP2021529738A (ja) 2021-11-04
MA52948B1 (fr) 2024-02-29
HUE064744T2 (hu) 2024-04-28
TWI826471B (zh) 2023-12-21
NI202000092A (es) 2021-03-23
UY38270A (es) 2020-01-31
DK3810602T3 (da) 2023-12-11
KR20210022655A (ko) 2021-03-03
AR114972A1 (es) 2020-11-11
GB201810092D0 (en) 2018-08-08
PE20210181A1 (es) 2021-01-29
SG11202010450VA (en) 2021-01-28
PH12020500673A1 (en) 2021-05-31
MD3810602T2 (ro) 2024-03-31
BR112020025869A2 (pt) 2021-03-23
FI3810602T3 (fi) 2023-12-21
EP3810602B1 (en) 2023-11-01
CA3101238A1 (en) 2019-12-26
DOP2020000249A (es) 2021-02-28
ES2967983T3 (es) 2024-05-06
RS64932B1 (sr) 2023-12-29
EP4335439A3 (en) 2024-05-15
AU2019289888A1 (en) 2020-11-12
IL279554A (en) 2021-01-31
CU20200096A7 (es) 2021-08-06
CO2020014586A2 (es) 2021-03-08
ECSP20075270A (es) 2021-02-26
US20200039945A1 (en) 2020-02-06
MX2020012723A (es) 2021-05-14
TW202016103A (zh) 2020-05-01
LT3810602T (lt) 2024-01-25
CR20210032A (es) 2021-02-11
MA52948A (fr) 2021-04-28
EP3810602A1 (en) 2021-04-28
CL2020003219A1 (es) 2021-06-11
US20220153710A1 (en) 2022-05-19
EP4335439A2 (en) 2024-03-13

Similar Documents

Publication Publication Date Title
EA202092451A1 (ru) Соединения
CY1120705T1 (el) Καινοφανεις αναστολεις αποακετυλασων ιστονων
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
EA202092263A1 (ru) Аминопиридиновые производные в качестве ингибиторов ctps1
EA201691625A1 (ru) Ароматические гетероциклические соединения как противовоспалительные соединения
EA201791684A1 (ru) Селективные ингибиторы bace1
EA201591491A1 (ru) Соединения тетрагидропирролотиазина
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
BR112017006253A2 (pt) novos compostos
EA201792021A1 (ru) Ингибитор jak
EA201690911A1 (ru) Соединения диметилбензойной кислоты
EA202090368A1 (ru) Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1)
EA201592183A1 (ru) Ингибиторы bace
CY1124413T1 (el) Ανταγωνιστες του υποδοχεα cgrp
CO2018004213A2 (es) Compuesto piranodipiridínico
EA201491852A1 (ru) Новые пиразольные соединения
CY1125355T1 (el) Πεντακυκλικη ενωση
EA201990238A1 (ru) ФОСФОРСОДЕРЖАЩИЕ ПРОЛЕКАРСТВА СТИМУЛЯТОРОВ sGC
ZA202101487B (en) Novel compounds
CY1123406T1 (el) Παραγωγο τριαζολοπυραζινονης χρησιμο ως ενας ανθρωπινος pde1 αναστολεας
EA202190989A1 (ru) Новый способ синтеза производных пиперазинил-этокси-бромфенила и их применение в получении содержащих их соединений
CY1119540T1 (el) Υποκατασταθεντα απο γλυκοπυρανοσυλιο παραγωγα ινδολο-ουριας και η χρηση τους ως αναστολεις sglt
EA201991141A1 (ru) Усилители bmp
EA201791596A1 (ru) Пиразоловые соединения